Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, July 12, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

Directors are selling Zeltiq Aesthetics, a medical tech company, too cheaply through an unfair process to Allergan, for $56.50 a share or $2.5 billion, shareholders say in Federal Court.

SAN FRANCISCO – Directors are selling Zeltiq Aesthetics, a medical tech company, too cheaply through an unfair process to Allergan, for $56.50 a share or $2.5 billion, shareholders say in Federal Court.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...